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Accepted 5 November 2009Most of the metastatic cervical lymphadenopathy results
from the upper aerodigestive tract [1]. Asymptomatic primary
ovarian cancer in the presence of metastatic left supra-
clavicular lymph nodes is rare [2]. Whether to identify the
primary tumor or to manage Stage IV ovarian cancer repre-
sents a clinical dilemma. We report a rare case of metastatic
adenocarcinoma of the left supraclavicular fossa resulting
from occult primary ovarian cancer.
A healthy 53-year-old menopausal woman, parity 2002,
presented with a growing lump as large as 8 6 3 cm in her
left supraclavicular fossa; she had had the mass for 3 months,
which on biopsy was diagnosed as a metastatic papillary
tumor (Fig. 1A). She underwent panendoscopy (nasolaryngo-
scopy, bronchoscopy, gastroenteroscopy) and a series of
imaging studies for primary malignancy, which demonstrated
only lymphadenopathy in the left axillary region to the
supraclavicular region (Fig. 2A). Finally, abdominal computed
tomography showed a right pelvic mass measuring
13.5 7.4 10.5 cm with a cystic component and enlarged
lymph nodes from the para-aortic to paracaval space.
The patient had a gynecological oncology consultation and
underwent exploratory laparotomy. The histopathology
confirmed papillary serous cystoadenocarcinoma of both
ovaries, coexisting with omentum cake and enlarged pelvic
lymph nodes. The patient underwent a debulking operation with
a total abdominal hysterectomy, bilateral salpingo-oophorec-
tomy, omentectomy, and lymph node dissection. However,
because of unresectable status of multiple tumor metastases to
the para-aortic, axillary, and supraclavicular lymph nodes, the* Corresponding author. Department of Obstetrics and Gynecology, Tri-
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doi:10.1016/j.tjog.2011.01.003surgery was categorized as suboptimal. The final diagnosis was
papillary serous cystoadenocarcinoma of the ovaries, Interna-
tional Federation of Gynecology and Obstetrics Stage IV
(pT3bN1M1) (Fig. 1B). The patient underwent adjuvant chem-
otherapywith paclitaxel and paraplatin following the suboptimal
debulking operation. The patient tolerated the chemotherapeutic
regimens well; the tumor markers dropped to normal range after
four courses of chemotherapy (Fig. 3). Magnetic resonance
imaging also showed no evidence of lymphadenopathy in the
supraclavicular region (Fig. 2B) after chemotherapy. Seven
months later, she remained disease-free.
Metastatic cervical carcinoma of unknown primary origin
accounts for approximately 3e5% of all head and neck
cancers. Among these cases, metastatic adenocarcinoma is
rarely identified, and attention should focus on diseases below
the clavicles, including diseases of the lung, breast, lower
digestive tract, and genitourinary tract.
Clinical surveillance should include medical history, phys-
ical examination, imaging, and panendoscopy. Fluorodeox-
yglucose positron emission tomography is another alternative if
the above surveys fail.
The subsequent treatment strategydepends ondisease-specific
prognostic factors. Although the most common site of extraper-
itonealmetastasis of ovarian cancer ismalignant pleural effusion,
the presence of metastatic supraclavicular lymphadenopathy is
rare. In a series of 100 autopsies on women who died of ovarian
carcinoma, the incidence of extra-abdominal lymphadenopathy
in the supraclavicular lymph nodes was only 4% [3].
The mainstay of epithelial ovarian cancer treatment is
surgical exploration with tumor debulking followed by
chemotherapy; the amount of residual tumor is an important
predictor of recurrence. A retrospective review conducted by
Curtin et al [4] revealed that age less than 65 years and
residual disease were independent predictors of outcome in 97
patients with Stage IV epithelial ovarian cancer.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) The histopathology of a metastatic lymph node (H&E, 200). (B) The histopathology of papillary serous cystoadenocarcinoma of the ovary (H&E,
200). Both show a picture of pleomorphic cells with papillary tumor growth. H&E¼ hematoxylin and eosin.
Fig. 2. (A) Left supraclavicular lymphadenopathy demonstrated by magnetic resonance imaging (arrow). (B) The lymphadenopathy disappeared after combined
chemotherapy with paclitaxel and paraplatin.
99W.-J. Wu et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 98e99Nevertheless, patients with supraclavicular nodal metas-
tases have poor prognoses and low probability of optimal
debulking. Many of these patients have associated comorbid-
ities as a result of their advanced malignancy, which impact
their surgical outcomes. For the sake of optimal resection with2,600
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Fig. 3. Level of tumor markers declined after debulking surgery and three
courses of chemotherapy.acceptable morbidity, Aletti et al [5] advocated using a triage
system to identify high-risk patients with Stage IV epithelial
ovarian cancer, including the presence of multiple liver
metastases or the combination of extensive peritoneal disease
and an American Society for Anesthesiologists classification
of 3 or 4.
For patients with less than optimal cytoreduction and
a significant adverse outcome, neoadjuvant chemotherapy or
alternative combination management should be used.References
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